KE Dipeptide, Lys-Glu
Evidence Grade C — Moderate human evidence. 62 published studies, 20 human. 0 registered clinical trials.
Vilon is a dipeptide (just two amino acids) from the Khavinson bioregulator programme, originally derived from thymus extract. It is the smallest peptide in the Khavinson programme, which raises fundamental questions about whether a molecule this small can exert the specific gene-regulatory effects proposed. No controlled human clinical trials have been conducted. It has no regulatory approval.
62 published studies: 20 human, 40 animal, 6 in-vitro, 2 reviews
Vilon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. Animal lifespan studies in mice reported by the Khavinson group form the evidence base.
As the smallest member of the Khavinson bioregulator peptide programme (just two amino acids), Vilon raises fundamental questions about whether a dipeptide can exert the specific gene-regulatory effects proposed. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Vilon may reverse age-related changes in chromatin structure. These proposals are part of the bioregulation theoretical framework, which posits that short peptides can modulate gene expression by interacting with DNA. These mechanisms have not been independently validated.
Research from the Khavinson group reports lifespan extension and tumour suppression in mouse studies, with consistent findings spanning 30+ years. However, the research is predominantly from Russian laboratories with limited methodology descriptions by Western standards. The fundamental question of how a two-amino-acid peptide could achieve sequence-specific DNA recognition — the proposed mechanism — remains scientifically debated. No large, properly controlled, double-blind trials meeting Western standards exist. No pharmacokinetic studies have been published. Products from unregulated channels lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
